Prevalence and specificity of immunoglobulin G and immunoglobulin A non-complement-binding anti-HLA alloantibodies in retransplant candidates.

The role of complement-binding donor-directed anti-human leukocyte antigen (HLA) antibodies in graft rejection is well established, whereas the prevalence and relevance of non-complement-binding (NCB) anti-HLA antibodies are less well defined. The aim of our study was to establish a sensitive and reliable test system for the detection and the specification of these NCB anti-HLA antibodies. Sera from 60 patients awaiting retransplantation were analysed for the presence of anti-HLA class I alloantibodies with complement-dependent cytotoxicity (CDC) tests. Immunoglobulin (Ig)G(all) anti-HLA class I and class II alloantibodies were differentiated on generic level by plate-based solid phase enzyme-linked immunosorbent assay. Subsequently, a modified bead-based (Luminex) assay was applied, allowing the investigation of IgG(2/4) NCB isotypes as well as IgA(1/2). The anti-HLA specificities of the NCB alloantibodies were determined and compared with known mismatches from previous transplants. Seventeen of the 60 sera (28%) were positive in the CDC increasing to 26 of 60 (43%) in the class I and 33 of 60 (55%) in the class II plate-based assay. Using the modified bead-based system 24 of 60 sera (40%) contained NCB IgG(2/4), which were mostly donor specific. In addition, a high prevalence of NCB IgA antibodies was detected (26 of 60 sera), which occurred independently of IgG(2/4) NCB, and half of which were donor specific. NCB anti-HLA alloantibodies, including the IgA isotype, can reliably be detected using the modified bead-based test system. These NCB alloantibodies had a high prevalence in retransplant candidates and were mostly donor specific.

[1]  B. Seliger,et al.  Comparison of the established standard complement-dependent cytotoxicity and flow cytometric crossmatch assays with a novel ELISA-based HLA crossmatch procedure. , 2006, Histology and histopathology.

[2]  A. Wiseman,et al.  Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  A. Salama,et al.  ELISA methods detect HLA antibodies with variable sensitivity , 2006, International journal of immunogenetics.

[4]  J. Alberú,et al.  Prevalence of HLA antibodies and its impact on graft function in a group of kidney transplant recipients: a cross-sectional study. , 2006, Transplantation proceedings.

[5]  R. Wassmuth,et al.  Anti-HLA class II antibodies in kidney retransplant patients. , 2005, Tissue antigens.

[6]  I. Doxiadis,et al.  Detection and specification of noncomplement binding anti-HLA alloantibodies. , 2004, Human immunology.

[7]  P. Terasaki.  Humoral Theory of Transplantation , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  M. Arias,et al.  Relationship of donor-specific class-I anti-HLA antibodies detected by ELISA after kidney transplantation on the development of acute rejection and graft survival. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  P. Dyer,et al.  Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome1 , 2003, Transplantation.

[10]  W. Reith,et al.  Deregulated MHC Class II Transactivator Expression Leads to a Strong Th2 Bias in CD4+ T Lymphocytes 1 , 2003, The Journal of Immunology.

[11]  G. Vidarsson,et al.  Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. , 2002, Blood.

[12]  P. Terasaki,et al.  Almost all patients who are waiting for a regraft of a kidney transplant have anti-HLA antibodies. , 2002, Transplantation proceedings.

[13]  S. Takemoto,et al.  All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies , 2002, Transplantation.

[14]  G. Opelz,et al.  Kidney graft failure and presensitization against HLA Class I and Class II antigens1 , 2002, Transplantation.

[15]  R. Bray,et al.  Sensitization and sensitivity: defining the unsensitized patient. , 2000, Transplantation.

[16]  S. Takemoto,et al.  Anti-HLA antibodies after solid organ transplantation. , 2000, Transplantation.

[17]  R. Bray,et al.  SENSITIZATION AND SENSITIVITY , 2000 .

[18]  R. Vaughan,et al.  Sensitization to HLA antigens occurs in 95% of primary renal transplant rejections. , 1995, Transplantation proceedings.

[19]  P. Terasaki,et al.  THE ROLE OF IgA ANTI‐HLA CLASS I ANTIBODIES IN KIDNEY TRANSPLANT SURVIVAL , 1993, Transplantation.

[20]  D. Gjertson,et al.  IN VITRO STUDIES TO EXPLAIN HIGH RENAL ALLOGRAFT SURVIVAL IN IGA NEPHROPATHY PATIENTS , 1993, Transplantation.

[21]  R. de Waal Malefyt,et al.  Regulation of the human IgE response by IL4 and IL13. , 1993, Research in immunology.

[22]  S. Ohlman,et al.  THE OCCURRENCE OF CYTOTOXIC AND NON‐COMPLEMENT‐FIXING ANTIBODIES IN THE CROSSMATCH SERUM OF PATIENTS WITH EARLY ACUTE REJECTION EPISODES , 1992, Transplantation.

[23]  J. D. de Vries,et al.  Transforming growth factor-beta directs IgA switching in human B cells. , 1992, Journal of immunology.

[24]  L. Hammarström,et al.  TGF-β1 induces germ-line transcripts of both IgA subclasses in human B lymphocytes , 1991 .